Below are the financial statements of Kymera Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Collaboration revenue | 47.07a | 78.59a | 46.83a |
| Operating expenses | — | — | — |
| Research and development | -240.25a | -189.08a | -164.25a |
| General and administrative | -63.53a | -55.04a | -43.83a |
| Impairment of long-lived assets | -4.93a | 0a | 0a |
| Total operating expenses | -308.71a | -244.12a | -208.08a |
| Loss from operations | -261.64a | -165.53a | -161.26a |
| Other income (expense) | — | — | — |
| Interest and other income | 38.03a | 18.76a | 6.62a |
| Interest and other expense | -0.25a | -0.2a | -0.18a |
| Total other income | 37.78a | 18.57a | 6.45a |
| Net loss | -223.86a | -146.96a | -154.81a |
| Reconciliation of net loss to net loss attributable to common stockholders | — | — | — |
| Net loss | -223.86a | -146.96a | -154.81a |
| Net loss attributable to common stockholders | -223.86a | -146.96a | -154.81a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.